

From the desk of  
**Hannah Deresiewicz**

As we approach the American Association for Cancer Research (AACR) Annual Meeting and particularly in light of recent news out of Washington and uncertainties across the industry, I am reminded of the critical importance of early research and development in the field of oncology. At Precision AQ, we are immensely proud to have played a role in supporting our clients as they bring groundbreaking and life-saving medicines to the forefront of the fight against cancer.

Over the years, our collaboration with innovative companies has led to significant advances in cancer treatment, offering hope and improved outcomes for countless patients. We are fortunate to have partnered with numerous oncology companies through preclinical and clinical development and, in some cases, all the way through to a successful launch. I'll never forget the first company I supported through a positive late-stage data readout and approval, and just how rewarding it felt to be a (very, very) small part of the team responsible for bringing forward a transformative new standard of care.

It never ceases to amaze me just how much the fundamental science continues to advance. It's easy to get distracted by news headlines or a more volatile stock market and lose sight of the incredible progress being made every single day—especially in times like these. That said, this is an industry that over the long-term has always traded on fundamentals and we remain fully confident that good companies with good medicines and good teams will continue to access capital and, ultimately, be successful in bringing new medicines to patients in need. At Precision, we are fortunate to have a front-row seat to biomedical innovation, partnering with companies that are developing new modalities or therapeutic.

Importantly, Precision's efforts in oncology go far beyond our IREC team. From clinical trial design and execution to medical scientific communications, advertising, and market access, the entire Precision family supports innovative companies developing new oncology treatments.

Helping our dedicated and passionate partners advance cancer care is core to our mission, and our clients' incredible efforts provide great optimism as we look to the future.

Hannah

## Company Celebrations

Last month, we gathered to celebrate **Lilian Stern's** **retirement** and her incredible legacy providing counsel to **more than 500 biotech companies** over the course of her illustrious career. Lilian has been instrumental as a leading advisor for biotech companies, partnering with many clients from IPOs to securing FDA approval for transformative medicines while building longstanding relationships spanning the investment community. At Stern IR and now Precision AQ, Lilian mentored **hundreds of employees and colleagues**, and we are so grateful for her dedication and partnership over the **last 27 years**.



Cheers, Lilian!



We also presented the **first annual Lilian Stern Award** to **Ross Bell**—a recognition reserved for team members who embody the values and vision of Lilian, as well as our Precision Principles of Client Service, Purpose, Accountability, Mutual Respect and Collaboration. Congratulations, Ross, on this well-deserved recognition! We are grateful for your contributions and excited to see all that you will accomplish.

## Community Support



Our Precision AQ team rode with Team Blackstone in the **2025 Cycle for Survival Event** to raise money for rare cancer research at Memorial Sloan Kettering Cancer Center (MSKCC). Cycle for Survival is the official rare cancer fundraising program of MSKCC.



**\$400+ million**

RAISED BY CFS SINCE 2007

**\$1 million**

RAISED BY BLACKSTONE IN 2025


**\$6 million**

RAISED BY BLACKSTONE SINCE 2013

**858**

THE NUMBER OF RIDERS ON THE BLACKSTONE TEAM THIS YEAR

## Client Shoutout



Congratulations to Precision AQ client, **Chimerix**, for its acquisition by **Jazz Pharmaceuticals** for **\$935 million**, which supports its strategy to further diversify its oncology franchise.

Dordaviprone is Chimerix' novel first-in-class small molecule imipridone that is under FDA review for accelerated approval as a treatment for patients with recurrent H3 K27M-mutant diffuse glioma.

## Street Moves People on the Move

### Buyside

**Isai Peimer**  
Joined Balyasny from Surveyor Capital

**Benjamin Bell**  
Joined Catalio Capital from T. Rowe Price Associates

**Calvin Nuyen**  
Left Verition. Next steps TBD

**Nathaniel Tracer**  
Moved to Passaic Capital from Ghost Tree Capital

**Rohan Ranadive**  
Moved from Altium Capital to Crestline Investors

**Seth Cassel**  
Left Orbimed. Next steps TBD

**Regina Salvat**  
Formerly at Sofinnova has joined Forbion

**Alison Yang**  
Joined Surveyor Capital from Avidity Partners

### Research

**Brian Balchin**  
Will be moving from the Jefferies EU team to the Jefferies US team

**Chris Raymond**  
Left Piper Sandler to join Raymond James

**Etzer Darout**  
Left BMO. Next steps TBD


**Boris Peaker**  
Has joined Titan Partners from TD Cowen

**Marty Auster**  
Joined Ventyx James from Ventyx Biosciences

**Jeff Hung**  
Left Morgan Stanley. Next steps TBD

**Dae Gon Ha**  
Left Stifel. Next steps TBD


## Access to Culture




Precision AQ is proud to partner with **Uncommon Productions** to invite you to join a private screening of the forthcoming documentary:

**Cracking the Code: Phil Sharp and the Biotech Revolution.**


Click below to see the trailer and to RSVP for the Bay Area or NYC private screenings email [annemarie.fields@precisionaq.com](mailto:annemarie.fields@precisionaq.com)



**Cracking the Code**, narrated by **Mark Ruffalo**, is an inspiring story of vision, perseverance, and the power of science to change the world. **Phil Sharp's journey from a Kentucky farm boy to Nobel laureate** embodies the American Dream and the triumph of entrepreneurial spirit. His 1977 **groundbreaking discovery of RNA splicing** rewrote the rules of molecular biology and ignited a life-saving scientific revolution, laying the foundation for an industry that has become a cornerstone of global innovation and economic growth – and **transformed the health – and billions of patients worldwide.**



## Access to the Best & Brightest



**Harpreet Singh, MD**  
Chief Medical Officer  
Precision for Medicine CMO and former Division Director of Oncology at the U.S. Food and Drug Administration, Harpreet Singh, MD, sits down to share her observations on the most exciting things she heard at JPM25 and to share thoughts on driving innovations forward in 2025!

## Company Spotlight



This month's Precision AQ Client Company Spotlight is on oncology drug developer, **CytomX Therapeutics**. The company's highly focused, multi-modality **PROBODY®** pipeline is targeted to address major unmet needs in oncology with **unique antibody masking strategies** for tumor localization and enhancement of therapeutic index.

The Company's wholly-owned lead program, **CX-2051**, is being evaluated in a Phase 1 clinical trial as a treatment for advanced colorectal cancer. CX-2051 is a first-in-class, masked EpCAM-targeting ADC armed with a topoisomerase-1 payload, that is specifically designed to address the profound unmet need in colorectal cancer. EpCAM is highly expressed in more than 90 percent of colorectal cancers. The ongoing CX-2051 Phase 1 study is evaluating the seventh dose level, which is predicted to be in a biologically active range. CytomX expects to present initial data from this important study in the second quarter of 2025.

CytomX is also partnered with some of the world's leading pharmaceutical and biotechnology companies, such as Amgen, Astellas, Bristol Myers Squibb, Moderna and Regeneron, to bring life-saving new drugs to patients battling cancers.

We look forward to CytomX's continued success and to the initial data readout for CX-2051!

## Investor Conference List

April 2025

### Healthcare Investor Conferences

Dates	April 2025 Events	Locations
4/2	H.C. Wainwright 2nd Annual Artificial Intelligence Based Drug Discovery & Development Conference	Virtual
4/2-4/3	Kempen Life Sciences Conference	Amsterdam
4/7	Canaccord Genuity Horizons in Oncology	Virtual
4/7-4/10	Needham & Co. Annual Healthcare Conference	Virtual
4/8	Goldman Sachs Healthcare Thematic Seminar	New York
4/8-4/9	Stifel Targeted Oncology Days	Virtual
4/9-4/11	Oppenheimer Innovation on the Island Biotech Summit	San Juan, Puerto Rico
4/9-4/10	Jefferies & Venrock Host: Boston Biotech Summit	Boston
4/16-4/17	Piper Sandler Spring Biopharma Symposium	Boston
4/22-4/23	Citi's 2025 Biotech Innovation Forum	New York
4/29	Chardan's Trending Issues in Drug Development Conference	Virtual